Quality-of-life and beliefs about medication in relation to a therapy adherence intervention in resistant hypertension: the Resistant HYpertension: MEasure to ReaCh Targets trial.
| Autor: | Zeijen VJM; Department of Cardiology., Peeters LEJ; Department of Internal Medicine.; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam., Asman A; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam., Boersma E; Department of Cardiology., Massey EK; Department of Internal Medicine., van Dijk L; Netherlands Institute for Health Services Research (NIVEL), Utrecht.; Department of PharmacoTherapy, Epidemiology and Economics (PTEE), Groningen Research Institute of Pharmacy, Faculty of Science and Engineering, University of Groningen, Groningen, the Netherlands., Daemen J; Department of Cardiology., Versmissen J; Department of Internal Medicine.; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of hypertension [J Hypertens] 2024 Oct 01; Vol. 42 (10), pp. 1687-1694. Date of Electronic Publication: 2024 May 23. |
| DOI: | 10.1097/HJH.0000000000003780 |
| Abstrakt: | Objective: To assess the impact of personalized feedback on therapy adherence testing results on quality of life and beliefs about medication in patients with resistant hypertension, as well as to identify patient-oriented predictors of therapy adherence. Methods: This study was a prespecified post hoc analysis of the multicenter randomized controlled trial Resistant HYpertension: MEasure to ReaCh Targets (RHYME-RCT). Patients were randomized to a personalized feedback conversation on measured antihypertensive drug levels additional to standard-of-care, or standard-of-care only. The primary outcomes consisted of EuroQol EQ-5D-5L and Beliefs about Medicine Questionnaire (BMQ) scores at 12 months. Results: A total of 56 patients with median age 61.5 [25th-75th percentile: 55.8-69.3] years (21.4% women) were included. Mean blood pressure ±SD was 149.8/84.1 ± 14.9/13.8 mmHg while being on a median of 5.6 [4.8-7.3] defined daily dosages (DDD) of antihypertensive drugs. At 12 months, no differences were observed in EQ-5D-5L index (0.81 [0.69-0.89] vs. 0.89 [0.73-1.00]; P = 0.18) and visual analogue scale score on general patient-perceived health (70 [60-80] vs. 70 [60-82]; P = 0.53) between the intervention-arm and the standard-of-care only-arm. Likewise, individual EQ-5D-5L domain scores and BMQ scores did not differ between both arms. Irrespective of the intervention, independent positive predictors of the percentage adherence were patient age, EQ-5D-5L index score, BMQ-specific necessity score and concern score, whereas the total number of drugs prescribed was a negative predictor. Conclusion: Within this prespecified subanalysis of the randomized RHYME-RCT trial, implementation of a personalized feedback conversation targeting therapy adherence did not improve health-related quality-of-life and beliefs about medication in patients with resistant hypertension. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|